The 2018 Start-up Slams are sponsored by:

The winners of the 2018 Start-up Slams are:

Elasmogen

Elasmogen Ltd is discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.

www.elasmogen.com

Peptomyc

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

www.peptomyc.com

Discover below the start-ups who pitched during BioFIT 2018:

  • THERAPEUTICS – CANCER | IMMUNO-ONCOLOGY
  • DELIVERY | DISCOVERY | RESEARCH TOOLS
  • PRODUCTION TOOLS
  • DIAGNOSTICS
  • THERAPEUTICS – OTHER INDICATIONS

2018 Start-up Slams Agenda

Tuesday, December 4th | 2.30 – 4.00 pm

THERAPEUTICS – CANCER | IMMUNO-ONCOLOGY

OncoQR ML GmbH (AT)

  • Unique novel vaccine for immuno-oncology – target-specific and highly controllable
  • Simultaneous activation of the B-cell and T-cell path without inducing auto-immune disease or triggering side-effects
  • Incredible IgG titres with very low amount of vaccine

 

Peptomyc S.L. (ES)

  • Cancer therapy
  • Peptide therapeutics
  • Anti-Myc therapy

 

 Odimma (FR)

  • Personalised Medicine
  • Cancer Immunotherapy
  • Neoantigens

 

 OPSYON (DE)

  • Fusion tumor targeting and immune checkpoint blockade
  • Bifunctional antibody fusion protein to reduced side effects
  • Next‐generation immune checkpoint inhibitor

 

LIfT BioSciences (UK)

  • First-in-class neutrophil based allogeneic innate cell therapy (ATMP) for solid tumours
  • Clinical trial evidence of safety and 80% tumour necrosis
  • Destroys all solid tumours, irrespective of mutation or strain

 

 Tubulis (DE)

  • Superior Antibody Drug Conjugates (ADCs) for targeted cancer therapy
  • Next-gen ADC conjugation
  • Catalyzing successful ADC development and overcoming existing obstacles

Wednesday, December 5th | 9.00 – 10.30 am

DELIVERY | DISCOVERY | RESEARCH TOOLS

MyLife Technologies (NL)

  • Nanoporous microneedle technology
  • Dermal drug delivery
  • Peptides, small molecules, vaccines

 

ATLANGRAM (FR)

  • Antibiotic
  • Resistance
  • Drug delivery

 

Mind the Byte (ES)

  • Drug Discovery
  • Artificial Intelligence
  • Cloud Computing

 

InBrain Pharma (FR)

  • Brain Infusion
  • Neurodegenerative diseases
  • Parkinson’s disease

PRODUCTION TOOLS

NUMAFERM (DE)

  • Biomade Peptides
  • Efficient and Reliable Bioproduction of Peptides
  • Short ramp-up

 

 UGISense AG (DE)

  • Ugimer™ antisense-technology
  • Proprietary platform technology
  • Drug development in collaboration with industrial partners

Wednesday, December 5th | 2.00 – 3.30 pm

DIAGNOSTICS

Carmentix (SG)

  • Diagnostics
  • Preterm Birth
  • Data Mining

 

Sencet (FR)

  • Cancer diagnostics
  • Characterization of circulating tumor cells
  • Single Cell analysis

THERAPEUTICS – OTHER INDICATIONS

Phyteau (US)

  • Diabetes, obesity and metabolism
  • Enteroendocrine cell receptor agonists
  • Completely safe, side-effect-free

 

APIOS (FR)

  • Bone reconstruction
  • Orthobiologics
  • Drug delivery

 

Madam Therapeutics (NL)

  • Anti-infectives
  • Anti-microbial resistance
  • Antibiotics

 

MTact (FR)

  • Alzheimer disease
  • Microtubules targeting agents
  • First-in-class

 

Op2Lysis (FR)

  • Intracerebral Hemorrhage (ICH) or hemorrhagic stroke
  • Biotechnology
  • MoA = safe and effective evacuation of brain hematoma

 

Elasmogen Ltd (UK)

  • SoloMERs
  • Biologics
  • Site-specific